Polymorphism of genes-candidates of renin-angiotensin-aldosteronovy system (ACE, AGT, AGTR1) and effectiveness of treatment of arterial hypertension. Results of research in Mountain Shoria

Aim. To study the dependence of the effectiveness of antihypertensive therapy on the polymorphic variants of candidate genes of the RAAS (ACE, AGT, AGTR1) in patients with hypertension (АH) of the population of Mountain Shoria. Materials and methods. In the conditions of the expeditions from 2013 to 2017, the population of Mountain Shoria was surveyed. Included 1409 people 18 years and older. Blood pressure monitoring was carried out as a result of office measurement, according to the standard recommendations of National Guidelines of the Russian Society of Cardiology/the Russian Medical Society on Arterial Hypertension (2010). As a result of the survey, patients with AH were identified for further observation (597 people) who need medical antihypertensive treatment. Repeat screening was conducted in a year. The criterion for inclusion in prospective observation of patients with hypertension was: regular intake of prescribed medication. 253 respondents were surveyed: indigenous (156 people) and non-indigenous (97 people) nationality. All patients underwent a standard examination, including the collection of complaints and anamnesis, an assessment of objective status, laboratory and instrumental studies. Polymorphisms of genes ACE (I/D, rs 4340), AGT (c.803T> C, rs699), AGTR1 (A1166C, rs5186) were tested using polymerase chain reaction. Results. Dynamic observation of patients with hypertension found that in the cohort of Shors the target level of blood pressure reached the owners of heterozygous I/D and minor D/D genotypes of the ACE gene, carriers of T/C and C/C genotypes of the AGT gene and the homozygous genotype A/A of the AGTR1 gene. In the non-indigenous nationality cohort, only carriers of the D/D genotype of the ACE gene. Conclusion. National differences were identified with respect to the sensitivity of the pharmacological response to treatment, which once again proves the important role of taking into account the ethnic factor in the choice of drug.

ethnos, antihypertensive therapy, treatment efficacy, renin-angiotensin-aldosterone system

1. Габитов Н.И. Артериальная гипертензия как сердечно-сосудистый синдром с наследственной предрасположенностью. Башкирский химический журнал. 2006; 13 (4): 43-4.

2. Николаев Н.А., Скирденко Ю.П., Бунова С.С. и др. Рациональная фармакотерапия в кардиологии: от рутинного контроля к эффективному управлению. Рациональная фармакотерапия в кардиологии. 2017; 13 (5): 609-14. DOI: 10.20996/1819-6446-2017-13-5-609-614

3. Сычев Д.А., Сулейманов С.Ш., Кукес В.Г. Персонализированная медицина как путь к рациональному применению лекарственных средств: предпосылки, реалии, проблемы и перспективы для отечественной системы здравоохранения. Здравоохранение Дальнего Востока. 2010; 1 (43): 2-7.

4. Бабак О.Я., Кравченко Н.А., Виноградова С.В. Генетические аспекты эффективности фармакотерапии при сердечно-сосудистой патологии. Украинский терапевтический журнал. 2006; 2: 92-9. DOI: 864125209047810_ 21092009170253

5. Степанов В.А. Геномы, популяции, болезни: этническая геномика и персонифицированная медицина. Acta naturae. 2010; 2 (4): 18-34. DOI: Stepanov-ActaNaturae-2010-2(4)-18-34-Review2

6. Даренская М.А. Этнические и региональные аспекты патологических процессов у человека. Бюллетень ВСНЦ СО РАМН. 2012; 2 (84): 152-9.

7. Мулерова Т.А., Максимов С.А., Огарков М.Ю. и др. Ассоциации факторов сердечно-сосудистого риска и генетических маркеров с наличием артериальной гипертензии у населения Горной Шории. Рациональная фармакотерапия в кардиологии. 2018; 14 (5): 678-86. DOI: https://doi.org/10.20996/1819-6446-2018-14-5-678-686

8. Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Российский кардиологический журнал. 2014; 1 (105): 7-94.

9. Котловский М.Ю., Котловская О.С., Оседко О.Я. и др. Полиморфизм гена ангиотензинпревращающего фермента у людей с гипертонической болезнью и хронической формой ИБС. Фундаментальные исследования. 2011; 11 (1): 49-52.

10. Heidari F, Vasudevan R, Mohd Ali SZ et al. Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene among Malay male hypertensive subjects in response to ACE inhibitors. J Renin Angiotensin Aldosterone System 2015; 16 (4): 872-9. DOI: 10.1177/1470320314538878

11. Stavroulakis GA, Makris TK, Krespi PG et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovascular Drugs and Therapy 2000; 14 (4): 427-32.

12. Srivastava K, Chandra S, Bhatia J et al. Association of angiotensinogen (M235T) gene polymorphism with blood pressure lowering response to angiotensin converting enzyme inhibitor (Enalapril). J Pharmacy Pharmaceutical Sci 2012; 15 (3): 399-406.

13. Filigheddu F, Argiolas G, Bulla E et al. Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. Pharmacogenomics 2008; 9 (10): 1419-27. DOI: 10.2217/14622416.9.10.1419

14. Gong HT, Ma XL, Chen BX et al. Polymorphisms of the angiotensin II type 1 receptor gene affect antihypertensive response to angiotensin receptor blockers in hypertensive Chinese. Genet Mol Res 2013; 21 (12): 2068-75. DOI: 10.4238/2013.June.21.2

15. Nakamura Y, Tamaki S, Uchida Y et al. Angiotensin converting enzyme genotype influences the response to the angiotensin II receptor antagonist losartan in patients with hypertension. Hypertension Res 2004; 27 (3): 137-40. DOI: https://doi.org/10.1291/hypres.27.137

16. Kolovou V, Lagou E, Mihas C et al. Angiotensinogen (AGT) M235T, AGT T174M and Angiotensin-1-Converting Enzyme (ACE) I/D Gene Polymorphisms in Essential Hypertension: Effects on Ramipril Efficacy. Open Cardiovascular Med J 2015; 29 (9): 118-26. DOI: 10.2174/1874192401509010118

17. Milionis HJ, Kostapanos MS, Vakalis K et al. Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome. J Renin Angiotensin Aldosterone Syst 2007; 8 (4): 181-9. DOI: 10.3317/jraas.2007.027

18. Zhang N, Cui H, Yang L et al. Effect of angiotensin II type I receptor A1166C polymorphism on benazepril action in hypertensive patients: a family-based association test study. Arch Pharm Res 2012; 35 (10): 1817-22. DOI: 10.1007/s12272-012-1015-9